TIM4 expression of dendritic cells and inflammation effects in OVA-induced asthma model treated with lentinan

doi:10.12092/j.issn.1009-2501.2018.09.005

Abstract

Abstract:

AIM: To study the expression of TIM4 in dendritic cells and the effect of inflammation in OVA-induced asthma model mice treated with lentinan. METHODS: Balbc female mice were randomly divided into three groups: normal control group, asthma model group, lentinan treatment group. The asthma model was induced by OVA in mice. In the treatment group, lentinan was injected intraperitoneally every day from the 7th day, and the asthma model group was injected intraperitoneally with physiological saline instead of lentinan. The expression of TIM4 in dendritic cells was detected by flow cytometry in mononuclear cells from spleen. ELISA was used to detect the concentration of MCP-1 and IL-4 in the serum. Q-PCR was used to detect the expression of TIM4 in lung tissue and HE staining for lung. RESULTS: After treatment, lentinan could down-regulate the expression of TIM4 in dendritic cells from spleen (P<0.05), decrease the concentration of IL-4 and MCP-1in the serum (P<0.05, P<0.01). The expression of TIM4 RNA in lung tissue was decreased (P<0.05). HE staining showed that the inflammation of the lung tissue in the treatment group was significantly reduced. CONCLUSION: Lentinan can inhibit the expression of TIM4 in dendritic cells, reduce the concentrations of inflammatory cytokines such as IL-4 and MCP-1, and inhibit the inflammatory response in OVA-induced asthma model.

Key words: lentinan, asthma, TIM4, dendritic cells, MCP-1, OVA

CLC Number:

R965.2

CHEN Ye, HE Shoudi, HU Zhili, FENG Bin. TIM4 expression of dendritic cells and inflammation effects in OVA-induced asthma model treated with lentinan[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 998-1002.

References

［1］Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches［J］. Nat Med, 2012, 18(5):716-725.
［2］赵文英, 陈冬云, 陈景华. 香菇多糖联合吉西他滨+顺铂方案一线治疗晚期非小细胞肺癌近期疗效与不良反应观察［J］. 中国临床药理学与治疗学, 2013, 18(1):71-77.
［3］Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma［J］. Nat Rev Immunol, 2008, 8(3):193-204.
［4］Vroman H, Van d BB, Kool M. Mode of dendritic cell activation: the decisive hand in Th2/Th17 cell differentiation. Implications in asthma severity ［J］ ? Immunobiology, 2015, 220(2):254-261.
［5］杨晓燕, 曾繁典. 支气管哮喘的药物治疗［J］. 中国临床药理学与治疗学, 2000, 1(4):374-377.
［6］晏建英, 陈叶, 冯斌. 香菇多糖对卵蛋白诱导小鼠急性哮喘模型免疫调节的影响［J］. 四川医学, 2016, 37(11):1212-1215.
［7］Kay AB. The Role of T Lymphocytes in Asthma［J］. Chem Immunol Allergy, 2006, 91(91):59-75.
［8］Balamayooran G, Batra S, Balamayooran T, et al. Monocyte chemoattractant protein 1 regulates pulmonary host defense via neutrophil recruitmentduring Escherichia coli infection ［J］. Infect Immun, 2011, 79(7):2567-2577.
［9］Noel W, Hassanzadeh G, Raes G, et al. Infection stage-dependent modulation of macrophage activation in Trypanosoma congolense-resistant and -susceptible mice ［J］. Infect Immun, 2002, 70(11):6180-6187.
［10］Meyers JH, Chakravarti S, Schlesinger D, et al. TIM-4 is the ligand for TIM-1, and the TIM-1|［ndash］TIM-4 interaction regulates T cell proliferation［J］. Nat Immunol, 2005, 6(5):455-464.
［11］Rodriguez-Manzanet R, Meyers JH, Balasubramanian S, et al. TIM-4 expressed on APCs induces T cell expansion and survival［J］. J Immunol, 2008, 180(7):4706-4713.
［12］Vroman H, van den Blink B, Kool M. Mode of dendritic cell activation: the decisive hand in Th2/Th17 cell differentiation. Implications in asthma severity ［J］ ? Immunobiology, 2015, 220(2):254-261.
［13］Jiang Y, Beller DI, Frendl G, et al. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes［J］. J Immunol, 1992, 148(8):2423-2428.
［14］Gao Y, Nish SA, Jiang R, et al. Control of T Helper 2 Responses by Transcription Factor IRF4-Dependent Dendritic Cells［J］. Immunity, 2013, 39(4):722-732.
［15］Plantinga M, Guilliams M, Vanheerswynghels M, et al. Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper ［15］cell-mediated immunity to house dust mite allergen［J］. Immunity, 2013, 38(2):322-335.
［16］Jakubzick C, Helft J, Kaplan TJ, et al. Optimization of methods to study pulmonary dendritic cell migration reveals distinct capacities of DC subsets to acquire soluble versus particulate antigen［J］. J Immunol Methods, 2008, 337(2):121-131.
［17］Larson RP, Comeau MR, Ziegler SF. Cutting edge: allergen-specific CD4 T cells respond indirectly to thymic stromal lymphopoietin to promote allergic responses in the skin［J］. J Immunol, 2013, 190(9):4474-4477.
［18］Vetvicka V. Glucan-immunostimulant, adjuvant, potential drug［J］. World J Clin Oncol, 2011, 2(2):115-119.
［19］江益平, 马方励, 周联, 等. 香菇多糖对免疫抑制小鼠肠道派氏结T细胞的影响［J］. 中国药理学通报, 2011, 27(9):1236-1239.
［20］Wang SX, Liu QY, Li Y. Lentinan ameliorates burn sepsis by attenuating CD4+, CD25+, Tregs［J］. Burns, 2016, 42(7):1513-1521.

[1]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[2]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[3]	HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50.
[4]	DENG Zhaoya, LI Yan, LIU Jian, HUANG Yinjiu. Study on the inhibition of compound salvia miltiorrhiza on the proliferation of ovarian cancer cells and its preliminary mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 526-534.
[5]	ZHANG Xiaoyi, KUAI Zheng, ZOU Yunzeng. Research progress of β2 microglobulin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 390-396.
[6]	CAI Zichun, JIANG Yuanzhen, ZHANG Chunsheng, LI Jiming. Research progress and application prospects of circRNA in cardiovascular diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 397-404.
[7]	DU Chen, TIAN He, CAO Yang, WANG Yongjun, ZHANG Yan. Research progress on bone metabolism disorders associated with PCOS elucidated from endocrine hormones [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 328-333.
[8]	ZHAO Ziwen, FAN Fangtian, JIANG Zhijun. Induced bronchial associated lymphoid tissue (iBALT) formation and research of related lung diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 353-360.
[9]	YAO Yao, XIA Min, HOU Cong, HE Airong. Effects of ABT-737 on the growth and angiogenesis of ovarian cancer cells in the co-culture of TAMs and SKOV3 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 144-153.
[10]	LV Xiaohan, LIN Rong. Association of Lin28 with tumor, cardiovascular disease and diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 205-211.
[11]	YUE Ling, DU Junhong, LIU Xiao, LI Yulan, XU Feixue. Mechanisms of histone methylation and acetylation modifying enzymes in ovarian cancer and therapeutic advances [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1299-1306.
[12]	LIU Lu, CHEN Xiaoyan. Current status of clinical drug-drug interactions research of innovative small molecule drugs in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 863-875.
[13]	LU Ruibin, ZHAO Hui, XIE Qiuling, HU Lu, GUO Chaowan, PEI Yunlin, XIONG Sheng. Anti-FGF-2 nanobody inhibits rat corneal angiogenesis induced by alkali burn [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 609-615.
[14]	HUANG Yaqin, XUE Rong. Treatment of sleep disorder in patients with acute cerebrovascular disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 516-521.
[15]	SHI Yingzi, ZHAO Yang. Impact of China-US drug regulatory incentives on local innovative drug simultaneous development in multiple countries: An empirical study based on zanubrutinib [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 560-569.